TY - JOUR
T1 - Multicentric Castleman disease
T2 - A single center experience of treatment with a focus on autologous stem cell transplantation
AU - Abdallah, Nadine H.
AU - Habermann, Thomas
AU - Buadi, Francis K.
AU - Gertz, Morie A.
AU - Lacy, Martha Q.
AU - Rajkumar, S. Vincent
AU - Dingli, David
AU - Go, Ronald S.
AU - Hayman, Suzanne R.
AU - Kumar, Shaji K.
AU - Kourelis, Taxiarchis
AU - Warsame, Rahma
AU - Kapoor, Prashant
AU - Muchtar, Eli
AU - Hwa, Yi L.
AU - Fonder, Amie L.
AU - Hobbs, Miriam A.
AU - Lin, Yi
AU - Leung, Nelson
AU - Binder, Moritz
AU - Siddiqui, Mustaqeem A.
AU - Kyle, Robert A.
AU - Witzig, Thomas E.
AU - Dispenzieri, Angela
N1 - Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2022/4
Y1 - 2022/4
N2 - Castleman disease (CD) is a rare lymphoproliferative disease characterized by diverse clinical and pathologic features. Due to its rarity, there are limited studies comparing currently available therapies. The role of autologous stem cell transplantation (ASCT) in CD has not yet been established. In this paper, we describe the clinical characteristics, treatment choices, and outcomes in 34 Mayo Clinic patients diagnosed with multicentric CD from July 1, 2003 to April 30, 2018. Eighteen patients (53%) also met the criteria for POEMS, including 14 with the osteosclerotic variant. The first-line treatments included: steroid monotherapy (4), cytotoxic chemotherapy (6), rituximab alone (8) or with chemotherapy (2), anti-IL6 treatment (3), and ASCT (10). The median follow-up was 4.8 (range: 0.1–15.2) years. The 5- and 10-year overall survival rates were 84% and 71%, respectively. Sixteen patients received high-dose chemotherapy followed by ASCT during their disease course. Among those, 14 had multicentric CD associated with POEMS. There were no transplant-related deaths. All patients had at least a partial response to ASCT, most of whom achieved a complete response. The favorable outcomes seen with ASCT in this cohort suggest that transplantation may have a role in multicentric CD, particularly for patients with multicentric CD associated with POEMS.
AB - Castleman disease (CD) is a rare lymphoproliferative disease characterized by diverse clinical and pathologic features. Due to its rarity, there are limited studies comparing currently available therapies. The role of autologous stem cell transplantation (ASCT) in CD has not yet been established. In this paper, we describe the clinical characteristics, treatment choices, and outcomes in 34 Mayo Clinic patients diagnosed with multicentric CD from July 1, 2003 to April 30, 2018. Eighteen patients (53%) also met the criteria for POEMS, including 14 with the osteosclerotic variant. The first-line treatments included: steroid monotherapy (4), cytotoxic chemotherapy (6), rituximab alone (8) or with chemotherapy (2), anti-IL6 treatment (3), and ASCT (10). The median follow-up was 4.8 (range: 0.1–15.2) years. The 5- and 10-year overall survival rates were 84% and 71%, respectively. Sixteen patients received high-dose chemotherapy followed by ASCT during their disease course. Among those, 14 had multicentric CD associated with POEMS. There were no transplant-related deaths. All patients had at least a partial response to ASCT, most of whom achieved a complete response. The favorable outcomes seen with ASCT in this cohort suggest that transplantation may have a role in multicentric CD, particularly for patients with multicentric CD associated with POEMS.
UR - http://www.scopus.com/inward/record.url?scp=85122854668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122854668&partnerID=8YFLogxK
U2 - 10.1002/ajh.26466
DO - 10.1002/ajh.26466
M3 - Article
C2 - 35015310
AN - SCOPUS:85122854668
SN - 0361-8609
VL - 97
SP - 401
EP - 410
JO - American journal of hematology
JF - American journal of hematology
IS - 4
ER -